Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0YS1U
|
||||
| Former ID |
DIB018038
|
||||
| Drug Name |
sparsentan
|
||||
| Synonyms |
RE-021; retrophin; DARA-a (Dual Acting Receptor Antagonist of angiotension and endothelin receptors); compound 7 [PMID 15634011]
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Myocardial infarction [ICD9: 410; ICD10:I21, I22] | Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C32H40N4O5S
|
||||
| InChI |
InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35)
|
||||
| InChIKey |
WRFHGDPIDHPWIQ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Type-1 angiotensin II receptor | Target Info | Antagonist | [2] | |
| Endothelin-1 receptor | Target Info | Antagonist | [2] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| cGMP-PKG signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Vascular smooth muscle contraction | |||||
| Renin-angiotensin system | |||||
| Renin secretion | |||||
| Pathways in cancerhsa04020:Calcium signaling pathway | |||||
| cAMP signaling pathway | |||||
| Pathways in cancer | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling PathwayNetPath_16:IL4 Signaling Pathway | ||||
| PANTHER Pathway | Angiotensin II-stimulated signaling through G proteins and beta-arrestinP00019:Endothelin signaling pathway | ||||
| Pathway Interaction Database | Arf6 trafficking events | ||||
| Arf6 signaling events | |||||
| Angiopoietin receptor Tie2-mediated signalingendothelinpathway:Endothelins | |||||
| EGFR-dependent Endothelin signaling events | |||||
| PathWhiz Pathway | Angiotensin Metabolism | ||||
| Muscle/Heart Contraction | |||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (q) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
| G alpha (q) signalling events | |||||
| WikiPathways | ACE Inhibitor Pathway | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Peptide GPCRs | |||||
| Allograft Rejection | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP98:Prostaglandin Synthesis and Regulation | |||||
| Endothelin Pathways | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J Med Chem. 2005 Jan 13;48(1):171-9. | ||||
| REF 2 | J Med Chem. 2005 Oct 20;48(21):6523-43.Designed multiple ligands. An emerging drug discovery paradigm. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.